Pharmacokinetics and Concentration-Control Investigations of Mycophenolic Acid in Adults After Transplantation
- 1 February 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 22 (1) , 14-19
- https://doi.org/10.1097/00007691-200002000-00003
Abstract
Data have emerged that provide the scientific basis for therapeutic drug monitoring of mycophenolic acid (MPA) in transplant patients receiving mycophenolate mofetil (MMF), the parent drug, in combination with other immunosuppressive agents. There is a significant relationship between the dose-interval MPA AUC and risk for acute rejection based on retrospective investigations in renal and heart transplant patients and on prospective investigations in renal transplant patients. The MPA dose-interval AUC varies naturally by more than 10-fold in renal and heart transplant patients. Other significant sources of pharmacokinetic variability for MPA include the effects of concomitant medications, and the effects of disease states such as renal dysfunction and liver disease on the steady state MPA AUC. Individualized MMF dose evaluation, guided by MPA plasma concentrations, is becoming the standard of practice at a growing number of transplant centers worldwide because of these factors and because of the need to closely evaluate the immunosuppression afforded by MPA when a change in the immunosuppression regimen in stable transplant patients is planned. Investigations of therapeutic drug monitoring strategies with an emphasis on identifying an optimal abbreviated sampling strategy for MPA AUC estimation are ongoing. Based on the concentration-outcome studies and experience at the authors' institutions and other centers, the authors propose a set of therapeutic drug monitoring guidelines for MPA in stable renal and heart transplant patients for the immediate (first 3 months posttransplant) and maintenance (>3 months) periods. When MPA binding to human serum albumin is altered, as occurs in patients with significant renal dysfunction, liver disease, or a substantial reduction in human serum albumin concentration, the possibility of increased MPA free fraction and free concentration will need to be taken into account in the interpretation of MPA total concentrations.Keywords
This publication has 23 references indexed in Scilit:
- A RANDOMIZED DOUBLE-BLIND, MULTICENTER PLASMA CONCENTRATION CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ORAL MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION1Transplantation, 1999
- IMPAIRED RENAL FUNCTION, NOT ETHNICITY, ALTERS MYCOPHENOLIC ACID PHARMACOKINETICS IN AFRICAN-AMERICAN RENAL TRANSPLANT PATIENTSTransplantation, 1999
- MYCOPHENOLATE MOFETIL AND CYCLOSPORINE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC BLOOD STEM CELL TRANSPLANTATIONTransplantation, 1999
- Therapeutic monitoring of mycophenolic acid (MPA): Assays of immune function in peripheral blood predict efficacy for inhibition of histologic graft rejectionThe Journal of Heart and Lung Transplantation, 1999
- Characterization of Two UDP Glucuronosyltransferases That Are Predominantly Expressed in Human ColonBiochemical and Biophysical Research Communications, 1998
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998
- VARIABLE ORAL ABSORPTION OF CYCLOSPORINETransplantation, 1996
- Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patientsBritish Journal of Clinical Pharmacology, 1996
- A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1996
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995